(MedPage Today) — In the wake of a surprise FDA advisory committee vote on Thursday, the third time could be the charm for RP1 (vusolimogene oderparepvec), a melanoma drug candidate that’s already been rejected twice by the agency.
Despite doubts…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
